BookUwe M. Martens, editor.
Contents:
Imatinib Mesylate
Dasatinib
Nilotinib
Bosutinib: a potent second-generation tyrosine kinase inhibitor
Ponatinib: a third-generation inhibitor for the treatment of CML
Ruxolitinib
Ibrutinib
Pomalidomide
Enasidenib
Midostaurin: a multiple kinases inhibitor in acute myeloid leukemia and systemic mastocytosis
Venetoclax: targeting BCL2 in hematological cancers
Idelalisib
Carfilzomib
Acalabrutinib, a second-generation Bruton's tyrosine kinase inhibitor.
Location
Version
Call Number
Items